10 Under-the-Radar Healthcare Stocks to Watch for Long-Term Growth

Healthcare remains one of the most vital and transformative sectors in the stock market, offering innovations that save lives and reshape patient care. As global populations age and chronic disease rates climb, both established healthcare leaders and rising innovators are positioned to experience robust growth—presenting compelling opportunities for investors.

Below, we highlight 10 lesser-known healthcare stocks that could be excellent additions to your investment portfolio.

1. Certara (CERT)

Certara provides advanced bio-simulation software and services that speed up drug research and development. Leveraging artificial intelligence (AI), Certara’s solutions have supported more than 90% of all new FDA-approved drugs since 2014. The company is at the forefront of AI-driven progress in the healthcare industry, making it a strategic choice for those bullish on technological disruption in pharma.

2. Beam Therapeutics (BEAM)

Beam Therapeutics pioneers precision gene editing therapies, targeting genetic diseases such as sickle cell anemia. Its proprietary technology enables single DNA base edits, potentially offering safer alternatives to traditional CRISPR methods. With its lead asset, BEAM-101, showing promise in early trials, Beam sets itself up for long-term expansion through innovating in genetic medicine.

3. Inspire Medical Systems (INSP)

Inspire Medical Systems develops minimally invasive, neurostimulation implants to treat obstructive sleep apnea. Its unique Inspire therapy is FDA-approved and is gaining traction as an alternative to CPAP machines. With strong revenue growth and broadening international presence, Inspire is well-placed to capture a growing sleep apnea market.

4. Insulet (PODD)

Insulet specializes in the Omnipod, a leading tubeless insulin pump that streamlines diabetes management. Projecting robust double-digit revenue increases through 2025, Insulet stands out with its accessible technology and expansion efforts, particularly in underrepresented markets worldwide.

5. Krystal Biotech (KRYS)

Krystal Biotech focuses on innovative gene therapies for rare skin conditions. Its flagship product, Vyjuvek, treats dystrophic epidermolysis bullosa and is projected to achieve up to $400 million in annual revenue. The product's success enhances Krystal's pipeline credibility and opens further market opportunities.

6. LifeMD (LFMD)

LifeMD operates a fast-growing telehealth platform, specializing in virtual care for weight management, men’s health, and dermatology. Strategic partnerships, like with Novo Nordisk, propel substantial revenue growth. LifeMD is expanding into a broader virtual health ecosystem to capitalize on rising demand for online healthcare.

7. Option Care Health (OPCH)

Option Care Health leads in providing home and alternate-site infusion therapies for chronic and acute illnesses. As healthcare trends favor personalized and cost-efficient treatment, the company’s extensive network and high standards position it to meet growing needs in this evolving market.

8. Tempus AI (TEM)

Tempus AI utilizes big data and AI to advance diagnostics, especially in oncology and cardiology. Boasting clinical and molecular data from over 40 million patients, Tempus is projecting over 80% revenue growth this year alone. Its scalable, data-driven platform opens vast opportunities in personalized healthcare.

9. TransMedics Group (TMDX)

TransMedics has transformed organ transplants with its Organ Care System—currently the only FDA-approved device that extends viable transplant times for hearts, lungs, and livers. The company’s rapid revenue growth underscores strong demand and expansive opportunities worldwide.

10. Veeva Systems (VEEV)

Veeva Systems delivers cloud-based software for clinical, regulatory, and commercial functions among life sciences companies. Serving more than 1,000 firms, including leading pharmaceutical brands and biotech startups, Veeva is ideally positioned as the industry shifts to digital-first processes for compliance and innovation.

This content is for informational purposes only and does not constitute financial advice.